A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer. Issue 1 (15th July 2022)

• Record Type: Journal Article
• Authors: Matsuda, Chu; Kudo, Toshihiro; Morimoto, Yoshihiro; Kagawa, Yoshinori; Tei, Mitsuyoshi; Ide, Yoshihito; Miyoshi, Norikatsu; Takahashi, Hidekazu; Uemura, Mamoru; Takemasa, Ichiro; Satoh, Taroh; Mizushima, Tsunekazu; Murata, Kohei; Doki, Yuichiro; Eguchi, Hidetoshi
• Is Part Of: Annals of gastroenterological surgery. Volume 7:Issue 1(2023)
• Page Start: 81
• Page End: 90
• Publication Date: 2022-07-15
• Subjects: capecitabine -- irinotecan -- neoadjuvant chemotherapy -- oxaliplatin -- rectal cancer; Digestive organs -- Surgery -- Periodicals; 617.43
• DOI: 10.1002/ags3.12600
• Languages: English
• ISSNs: 2475-0328

Abstract

Abstract: Purpose: Addition of perioperative multi‐agent chemotherapy to the treatment strategy for locally advanced rectal cancer (LARC) may be a promising option. We conducted a phase II study to evaluate the safety and efficacy of capecitabine combined with oxaliplatin and irinotecan (XELOXIRI) as triplet neoadjuvant chemotherapy in patients with LARC. Methods: Patients received neoadjuvant irinotecan and oxaliplatin and capecitabine and then underwent total mesorectal excision. The primary study endpoint was the pathological complete response (pCR) rate. Results: Between June 2013 and December 2016, 55 patients were enrolled in the study. Forty‐two (77.8%) of 54 completed the study protocol. The pCR rate was 7.7% (95% CI 3.0% to 18.2%). The 3‐year local recurrence rate was 3.9%, the 3‐year disease‐free survival (DFS) rate was 77.3, and the 3‐year overall survival rate was 96.0%. Conclusion: XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS, and measures of safety met current standards. Abstract : XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS and measures of safety met current standards.